Mike Gallatin

Mike brings over 35 years of experience as a scientist and executive to the OncoResponse Scientific Advisory Board. He is a member of Frazier Healthcare Partners' Life Sciences team, has co-founded Calistoga (acquired by Gilead) and Stromedix (acquired by Biogen Idec) and served as President of Calistoga, which was the first company to demonstrate the clinical benefit of an isoform selective PI3K (idelalisib) inhibitor in hematologic malignancies. That drug, under the brand name Zydelig, received approvals from both the FDA and EMA in 2014 to treat chronic lymphocytic leukemia and follicular lymphoma. Mike was one of the founding scientists at ICOS Corporation, where he served as VP and Scientific Director. Mike's responsibilities at ICOS included discovery, preclinical research, medicinal chemistry, and process chemistry groups including those that helped generate and support the worldwide registration and launch of Cialis. Earlier, Mike developed expertise in the fields of immunology/inflammation and oncology while on the faculty at the Fred Hutchinson Cancer Center. Mike has also been a member of the Scientific Advisory Boards of the Keystone Symposia, Caprion, and the University of Texas Department of Chemistry.

Mike is currently is a member of the Therapeutic Advisory Board for FH V company AnaptysBio and is a member of the Board of Directors of EpiThany, Inc. Mike also serves as a member of the Executive Committee of the Board of Directors of the Benaroya Research Institute and is co-chairman of the University of Washington CoMotion Advisory Board for Therapeutics and Diagnostics. Mike received his PhD from the University of Alberta Department of Immunology. His doctoral research focused on genetic resistance to virally induced neoplastic disease and invasive mechanisms, including the first description of antigen gain associated with organ-specific tumor metastasis. While a Damon Runyon-Walter Winchell and American Cancer Society fellow at Stanford University in the lab of Irving Weissman, Mike discovered the first cell adhesion molecule implicated in site selective leukocyte traffic.